Home > News > WELCOME TO THE FOURTH AND LAST DAY OF #ESHCML2021
WELCOME TO THE FOURTH AND LAST DAY OF #ESHCML2021
October 10, 2021
23rd ANNUAL JOHN GOLDMAN CONFERENCE ON CHRONIC MYELOID LEUKEMIA: BIOLOGY AND THERAPY
October 7-10, 2021 - E-CONFERENCE FREE REGISTRATION
Co-organizers: Ravi Bhatia, Tim Brümmendorf, Mhairi Copland, Michael Deininger, Olivier Hantschel, François-Xavier Mahon, Danilo Perrotti, Jerry Radich, Delphine Réa
Advisory Committee: Jane Apperley, Susan Branford, Carlo Gambacorti-Passerini, François Guilhot, Rüdiger Hehlmann, Pierre Laneuville, Giuseppe Saglio, Charles Schiffer, Simona Soverini, Peter Valent, Rick Van Etten
JOIN US FOR THE FOURTH AND LAST DAY OF THE E-CONFERENCE:
11:00-13:00 Workshop for Non-Clinical Scientists #2 Single Cell Analysis Chairs: Mhairi Copland (Glasgow), Satu Mustjoki (Helsinki) Interactive Live Discussion at 12:20
13:00-13:25 ESH International John Goldman Research Award 2019: Presentation of Results Chair: Hervé Dombret (Paris), ESH President Use of machine learning to integrate clinical data and biomarkers to optimize prediction of TFR by Ilaria Pagnani Interactive Live Discussion at 13:20
14:00-14:30 Roundtable: Is TFR the right road to cure we should be pursuing? Chair: Jeff Lipton (Toronto)
Discussants: Jan Geissler (Munich), François-Xavier Mahon (Bordeaux), Moshe Talpaz (Ann Arbor)
14:30-14:58 Special Lecture (7): The biology and implications of clonal hematopoiesis by Tim Brümmendorf (Aachen) Interactive Live Discussion at 14:48
14:58-16:15 Scientific Session VII: Quality of Life and Co-Morbidities Chair: Susanne Saussele (Mannheim) Keynote presentation: The role of patient reported outcomes in the management of patients with CML: Are we doing it right? Are we doing enough? by Fabio Efficace (Chicago) Interactive Live Discussion at 15:16 Followed by selected abstracts Interactive Live Panel Discussion at 16:02
17:05-18:35 Scientific Session VIII: TKI Safety Chair: Kendra Sweet (Tampa) Keynote presentation: A deeper dive into the safety of TKIs by Carlo Gambacorti-Passerini (Monza) Interactive Live Discussion at 17:23 Followed by selected abstracts Interactive Live Panel Discussion at 18:21
Welcome message from the E-conference chairpersons!
Participants will be joining us from all over the world and from different time zones.
To make sure that everyone has access to the full scientific program at a convenient hour,
registration will allow participants to join both the LIVE PROGRAM (October 7-10, 2021)
and the PROGRAM ON DEMAND (September 27 - November 10, 2021).
The “Live Program” will be streamed live CEST time.
It will include Meet the Expert sessions, interactive panel discussions, Q&A periods and Mentored Poster Walks.
It will also include some pre-recorded lectures that will be streamed live, followed by their corresponding fully live Q&A period.
The “Program on Demand” is now available.
It will initially include the pre-recorded components of the scientific program.
It will be progressively enriched by the meeting’s live, interactive components which will be recorded real time during the meeting.
E-POSTERS:September 27 - November 10, 2021
The Poster Hall will also remain open until November 10, 2021.
The Mentored Poster Walks scheduled in the LIVE PROGRAM will also become available in the PROGRAM ON DEMAND.
VIRTUAL EXHIBITION: September 27 - November 10, 2021
We invite you to visit the Exhibition area as of September 27.
Our corporate partners will be pleased to welcome & chat with you.
ABOUT THE PROGRAM:
Speakers at this meeting will present the newest and often unpublished data relating to the (1) Biology of CML including the origin of BCR-ABL1, signal transduction, basis of disease progression, action of tyrosine kinase inhibitors and mechanisms underlying resistance to TKI, and (2) aspects of treatment including prediction and definition of responses, drugs used in combination, modern diagnostics and molecular monitoring, targeting residual stem cells, approaches to cure and treatment free remission.
The program will include:
John Goldman Prize Lecture
Janet Rowley Prize Lecture
iCMLf Prize Lecture
ESH John Goldman International Research Award presentations
Keynote lectures
Special lectures
Oral communications selected from submitted abstracts
Workshops for non-clinical scientists
Meet-the-Expert Sessions
Clinical and Biology manned poster walks
Special Clinical Symposium 2021
Educational Objectives:
Upon completion of this CME activity, participants should be able to:
1. Understand current and new concepts of the signal transduction pathways involved in chronic myeloid leukemia (CML) and the mechanisms of action of tyrosine kinase inhibitors and other new agents.
2. Have insight into the possible mechanisms of genomic instability that predisposes to formation of the BCR-ABL fusion gene and predispose also to disease progression and the consequences of such instability.
3. Define a leukemia stem cell and its relationship to disease kinetics in so far as current knowledge permits.
4. Evaluate the merits of various management decisions, e.g. how to start treatment for patients in the different phases of CML, how to assess success or failure of initial treatment, what approaches to consider for patients who have failed to respond well to initial treatment, including assessing the precise role of second and third generation TKIs and other non-molecular therapeutic approaches.
5. Review the current recommendations and discuss current concepts and challenges of monitoring individual patients with hematologic, cytogenetic and molecular (RQ-PCR) methods.
6. Assess the role of allogeneic stem cell transplantation in the management of CML.
7. Critically evaluate the possible role of the different immunotherapeutic approaches in the treatment of CML.
8. Discuss current data and ongoing research regarding treatment-free survival as an endpoint in CML management.
9. Discuss patient reported outcomes and their role in the management of patients with CML.
Join us on the 2021 Run.Ride.Cure challenge - Let's move towards a cure for CML
Choose between three different options to support the Run.Ride.Cure challenge:
*ESH conference programs are developed in strict scientific independence
with no input from corporate sponsors.
Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. AcceptRead More
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
